Working draft — Scientific review: pending | Regulatory review: pending | Not for external clinical or promotional use without independent verification
Back to Prescriber Hub
9
PrescriberLast reviewed: April 2026

Indication-Specific Clinical Pathways

Translate the evidence matrix into practical clinic workflows.

Learning Objectives

Apply the evidence matrix to real patient scenarios
Follow structured clinical pathways for each indication area
Identify red flags and stopping rules by indication

Core Content

Each pathway follows the same structure: clinical use case, molecule with strongest evidence, route/formulation, evidence level, UK status, patient selection, red flags, dosing evidence, monitoring, stopping rules, and references.

Seven pathways cover: Epilepsy, Psychiatry, Sleep, Neurology/Brain Injury, Dermatology, Female Health, and Pain.

Key Takeaways

  • 1Seven structured clinical pathways cover all indication areas
  • 2Each pathway follows the same systematic structure
  • 3Red flags and stopping rules are indication-specific
  • 4Topical evidence must not be extrapolated to oral use
  • 5Pain is exceptional specialist/research framing only

Knowledge Check

Q1. Can topical CBD dermatology evidence support oral CBD prescribing for skin conditions?

Downloadable Tools

Pathway decision trees

Visual decision trees for each of the 7 pathways

card

Clinic workflow checklist

Step-by-step workflow for pathway implementation

checklist

Tools are provided as templates for clinical practice. Adapt to your clinic's specific requirements.

References

  1. [1]CannabinoidEvidence.org. Clinical Evidence Matrix. 2026.
  2. [2]NICE. Cannabis-based medicinal products. NG144. 2019.
  3. [3]Epidyolex SmPC. GW Pharmaceuticals.
Module 8: Safety & InteractionsModule 10: Consent & Documentation

This material is educational and non-promotional. It does not constitute medical advice, prescribing advice, or a recommendation to use any medicine. Any use of an unlicensed medicine requires patient-specific clinical justification, informed consent, monitoring, pharmacovigilance and compliance with applicable regulatory requirements.